N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models

zu Verbundenen Objekten

Standort: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1758-9193

Umfang: Online-Ressource

Sprache: Englisch

Anmerkungen: online resource.

Erschienen in: N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models ; volume:9 ; number:1 ; day:4 ; month:10 ; year:2017 ; pages:1-12 ; date:12.2017
Alzheimer's research & therapy ; 9, Heft 1 (4.10.2017), 1-12, 12.2017

Klassifikation: Medizin, Gesundheit

Urheber: Wirths, Oliver

Beteiligte Personen und Organisationen: Walter, Susanne
Kraus, Inga
Klafki, Hans W.
Stazi, Martina
Oberstein, Timo J.
Ghiso, Jorge
Wiltfang, Jens
Bayer, Thomas A.
Weggen, Sascha
SpringerLink (Online service)

DOI: 10.1186/s13195-017-0309-z

URN: urn:nbn:de:1111-2017112812437

Rechteinformation: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Letzte Aktualisierung: 15.08.2025, 07:36 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.

Original beim Datenpartner anzeigen

Beteiligte

Wirths, Oliver
Walter, Susanne
Kraus, Inga
Klafki, Hans W.
Stazi, Martina
Oberstein, Timo J.
Ghiso, Jorge
Wiltfang, Jens
Bayer, Thomas A.
Weggen, Sascha
SpringerLink (Online service)

Ähnliche Objekte (12)

N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models

Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer’s disease and transgenic mouse models

Eisregen, [...]. [Partitur]

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia

Prediction of Alzheimer's Disease Using a Cerebrospinal Fluid Pattern of C-Terminally Truncated β-Amyloid Peptides

Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease

Glycoprotein NMB: a novel Alzheimer’s disease associated marker expressed in a subset of activated microglia

Transcriptomic profiling of sporadic Alzheimer’s disease patients

Use of Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany

Modeling Alzheimer’s disease in transgenic rats

Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?

C-terminally truncated Amyloid-β peptides in Alzheimer’s dementia: Deposition of Aβ37, Aβ38, and Aβ39 in the brains of patients with sporadic and familiar Alzheimer’s dementia and in transgenic mouse models.

N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models

Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer’s disease and transgenic mouse models

Eisregen, [...]. [Partitur]

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia

Prediction of Alzheimer's Disease Using a Cerebrospinal Fluid Pattern of C-Terminally Truncated β-Amyloid Peptides

Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease

Glycoprotein NMB: a novel Alzheimer’s disease associated marker expressed in a subset of activated microglia

Transcriptomic profiling of sporadic Alzheimer’s disease patients

Use of Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany

Modeling Alzheimer’s disease in transgenic rats

Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?

C-terminally truncated Amyloid-β peptides in Alzheimer’s dementia: Deposition of Aβ37, Aβ38, and Aβ39 in the brains of patients with sporadic and familiar Alzheimer’s dementia and in transgenic mouse models.

N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models

Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer’s disease and transgenic mouse models

Eisregen, [...]. [Partitur]

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia

Prediction of Alzheimer's Disease Using a Cerebrospinal Fluid Pattern of C-Terminally Truncated β-Amyloid Peptides

Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease

Glycoprotein NMB: a novel Alzheimer’s disease associated marker expressed in a subset of activated microglia

Transcriptomic profiling of sporadic Alzheimer’s disease patients

Use of Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany

Modeling Alzheimer’s disease in transgenic rats

Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?

C-terminally truncated Amyloid-β peptides in Alzheimer’s dementia: Deposition of Aβ37, Aβ38, and Aβ39 in the brains of patients with sporadic and familiar Alzheimer’s dementia and in transgenic mouse models.

Informationen zur Registrierung von Kultur- und Wissenseinrichtungen finden Sie hier.

Felder mit * müssen ausgefüllt werden.

Benutzername*

Bitte geben Sie Ihren Benutzernamen ein

E-Mail*

Bitte geben Sie Ihre E-Mail ein

Bitte füllen Sie dieses Feld nicht aus

Vorname

Nachname

Passwort*

Bitte geben Sie Ihr Passwort ein

Passwort bestätigen*

Bitte geben Sie das gleiche Passwort ein

Ich habe die Nutzungsbedingungen und die Datenschutzerklärung zur Erhebung persönlicher Daten gelesen und stimme ihnen zu. *

Dieses Feld ist ein Pflichtfeld.

Ich möchte den Newsletter der Deutschen Digitalen Bibliothek abonnieren. Siehe Informationen zum Newsletter-Abonnement.

Benutzerkonto angelegt

Ihr „Meine DDB“-Konto wurde erfolgreich angelegt. Bevor Sie sich in Ihrem Konto anmelden können, müssen Sie auf den Bestätigungslink in der Nachricht klicken, die wir gerade an die von Ihnen angegebene E-Mail-Adresse geschickt haben

N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models

Angaben zum Objekt

Verweise und Beziehungen

Klassifikation und Themen

Beteiligte, Orts- und Zeitangaben

Weitere Informationen

Datenpartner

Beteiligte

Ähnliche Objekte (12)

N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models

Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer’s disease and transgenic mouse models

Eisregen, [...]. [Partitur]

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia

Prediction of Alzheimer's Disease Using a Cerebrospinal Fluid Pattern of C-Terminally Truncated β-Amyloid Peptides

Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease

Glycoprotein NMB: a novel Alzheimer’s disease associated marker expressed in a subset of activated microglia

Transcriptomic profiling of sporadic Alzheimer’s disease patients

Use of Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany

Modeling Alzheimer’s disease in transgenic rats

Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?

C-terminally truncated Amyloid-β peptides in Alzheimer’s dementia: Deposition of Aβ37, Aβ38, and Aβ39 in the brains of patients with sporadic and familiar Alzheimer’s dementia and in transgenic mouse models.

N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models

Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer’s disease and transgenic mouse models

Eisregen, [...]. [Partitur]

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia

Prediction of Alzheimer's Disease Using a Cerebrospinal Fluid Pattern of C-Terminally Truncated β-Amyloid Peptides

Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease

Glycoprotein NMB: a novel Alzheimer’s disease associated marker expressed in a subset of activated microglia

Transcriptomic profiling of sporadic Alzheimer’s disease patients

Use of Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany

Modeling Alzheimer’s disease in transgenic rats

Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?

C-terminally truncated Amyloid-β peptides in Alzheimer’s dementia: Deposition of Aβ37, Aβ38, and Aβ39 in the brains of patients with sporadic and familiar Alzheimer’s dementia and in transgenic mouse models.

N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models

Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer’s disease and transgenic mouse models

Eisregen, [...]. [Partitur]

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia

Prediction of Alzheimer's Disease Using a Cerebrospinal Fluid Pattern of C-Terminally Truncated β-Amyloid Peptides

Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease

Glycoprotein NMB: a novel Alzheimer’s disease associated marker expressed in a subset of activated microglia

Transcriptomic profiling of sporadic Alzheimer’s disease patients

Use of Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany

Modeling Alzheimer’s disease in transgenic rats

Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?

C-terminally truncated Amyloid-β peptides in Alzheimer’s dementia: Deposition of Aβ37, Aβ38, and Aβ39 in the brains of patients with sporadic and familiar Alzheimer’s dementia and in transgenic mouse models.

Verbundene Objekte

Passwort zurücksetzen